{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=GLP-1+and+GIP&page=2",
    "query": {
      "intervention": "GLP-1 and GIP",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=GLP-1+and+GIP&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-09-28T11:16:18.159Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT07284875",
      "title": "Efficacy and Safety of Ribupatide in Participants Living With Obesity or Overweight With Weight-Related Comorbidities Who Do Not Have Diabetes",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Obesity",
        "Overweight"
      ],
      "interventions": [
        {
          "name": "Ribupatide",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Kailera",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 2340,
      "start_date": "2025-12-18",
      "completion_date": "2028-03",
      "has_results": false,
      "last_update_posted_date": "2026-09-03",
      "last_synced_at": "2026-09-28T11:16:18.159Z",
      "location_count": 24,
      "location_summary": "Anniston, Alabama • Birmingham, Alabama • Cullman, Alabama + 21 more",
      "locations": [
        {
          "city": "Anniston",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Cullman",
          "state": "Alabama"
        },
        {
          "city": "Sun City",
          "state": "Arizona"
        },
        {
          "city": "Escondido",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07284875"
    },
    {
      "nct_id": "NCT07793929",
      "title": "A Study to Evaluate the Impact of Renal Impairment on the Pharmacokinetics (PK) of Ribupatide",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "End Stage Renal Disease",
        "Renal Impairment",
        "Obesity",
        "Overweight"
      ],
      "interventions": [
        {
          "name": "Ribupatide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Kailera",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "18 Years to 85 Years"
      },
      "enrollment_count": 32,
      "start_date": "2026-09-08",
      "completion_date": "2028-02-08",
      "has_results": false,
      "last_update_posted_date": "2026-09-03",
      "last_synced_at": "2026-09-28T11:16:18.159Z",
      "location_count": 1,
      "location_summary": "San Antonio, Texas",
      "locations": [
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07793929"
    },
    {
      "nct_id": "NCT07640139",
      "title": "Estimating the Impact of Obesity Medications on Clinical and Economic Outcomes",
      "overall_status": "ENROLLING_BY_INVITATION",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Obesity"
      ],
      "interventions": [
        {
          "name": "Incretin-based therapies (GLP-1 and GLP-1/GIP)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Indiana University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "64 Years",
        "sex": "ALL",
        "summary": "18 Years to 64 Years"
      },
      "enrollment_count": 125000,
      "start_date": "2026-01-01",
      "completion_date": "2029-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-06-10",
      "last_synced_at": "2026-09-28T11:16:18.159Z",
      "location_count": 1,
      "location_summary": "Indianapolis, Indiana",
      "locations": [
        {
          "city": "Indianapolis",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07640139"
    },
    {
      "nct_id": "NCT06565611",
      "title": "A Phase 2 Study Evaluating the Co-Administration of Bremelanotide With Tirzepatide for the Treatment of Obesity",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Obesity"
      ],
      "interventions": [
        {
          "name": "bremelanotide",
          "type": "DRUG"
        },
        {
          "name": "tirzepatide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Palatin Technologies, Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 108,
      "start_date": "2024-08-05",
      "completion_date": "2025-03-31",
      "has_results": false,
      "last_update_posted_date": "2025-03-06",
      "last_synced_at": "2026-09-28T11:16:18.159Z",
      "location_count": 4,
      "location_summary": "DeLand, Florida • Oklahoma City, Oklahoma • North Charleston, South Carolina + 1 more",
      "locations": [
        {
          "city": "DeLand",
          "state": "Florida"
        },
        {
          "city": "Oklahoma City",
          "state": "Oklahoma"
        },
        {
          "city": "North Charleston",
          "state": "South Carolina"
        },
        {
          "city": "Chattanooga",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06565611"
    },
    {
      "nct_id": "NCT02363335",
      "title": "The Role of Phosphodiesterase Inhibitors in Incretin Secretion",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Volunteers"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "OTHER"
        },
        {
          "name": "Roflumilast/Sitagliptin",
          "type": "OTHER"
        },
        {
          "name": "Sitagliptin",
          "type": "OTHER"
        },
        {
          "name": "Roflumilast",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "National Institute on Aging (NIA)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "21 Years to 55 Years"
      },
      "enrollment_count": 29,
      "start_date": "2015-02-13",
      "completion_date": "2016-09-19",
      "has_results": false,
      "last_update_posted_date": "2026-07-28",
      "last_synced_at": "2026-09-28T11:16:18.159Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02363335"
    },
    {
      "nct_id": "NCT01951729",
      "title": "The Role of Cholinergic Signaling for Mediating the Effects of GIP and/or Xenin-25 on Insulin Secretion",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Pre-diabetes"
      ],
      "interventions": [
        {
          "name": "Control",
          "type": "DRUG"
        },
        {
          "name": "Xenin-25 without atropine",
          "type": "DRUG"
        },
        {
          "name": "GIP without atropine",
          "type": "DRUG"
        },
        {
          "name": "Placebo with atropine",
          "type": "DRUG"
        },
        {
          "name": "Xenin-25 with atropine",
          "type": "DRUG"
        },
        {
          "name": "GIP with atropine",
          "type": "DRUG"
        },
        {
          "name": "GIP plus Xenin-25 without atropine",
          "type": "DRUG"
        },
        {
          "name": "GIP plus Xenin-25 with atropine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Washington University School of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 15,
      "start_date": "2013-03-13",
      "completion_date": "2015-05",
      "has_results": false,
      "last_update_posted_date": "2018-05-25",
      "last_synced_at": "2026-09-28T11:16:18.159Z",
      "location_count": 1,
      "location_summary": "St Louis, Missouri",
      "locations": [
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01951729"
    },
    {
      "nct_id": "NCT01434901",
      "title": "The Effects of Bethanechol on Glucose Homeostasis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Type 2 Diabetes Mellitus"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Bethanechol (25 mg)",
          "type": "DRUG"
        },
        {
          "name": "Bethanechol (50 mg)",
          "type": "DRUG"
        },
        {
          "name": "Bethanechol (100 mg)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Washington University School of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 50,
      "start_date": "2011-08-15",
      "completion_date": "2014-07-07",
      "has_results": false,
      "last_update_posted_date": "2018-05-08",
      "last_synced_at": "2026-09-28T11:16:18.159Z",
      "location_count": 1,
      "location_summary": "St Louis, Missouri",
      "locations": [
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01434901"
    },
    {
      "nct_id": "NCT07431086",
      "title": "Study of Olatorepatide in Adult Participants Living With Overweight or Obesity in the US",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Overweight or Obesity"
      ],
      "interventions": [
        {
          "name": "Olatorepatide",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Regeneron Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 120,
      "start_date": "2026-03-16",
      "completion_date": "2026-12-18",
      "has_results": false,
      "last_update_posted_date": "2026-06-17",
      "last_synced_at": "2026-09-28T11:16:18.159Z",
      "location_count": 3,
      "location_summary": "Walnut Creek, California • Winter Park, Florida • San Antonio, Texas",
      "locations": [
        {
          "city": "Walnut Creek",
          "state": "California"
        },
        {
          "city": "Winter Park",
          "state": "Florida"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07431086"
    },
    {
      "nct_id": "NCT01951716",
      "title": "Effects of Xenin-25 on Insulin Secretion and Gastric Emptying in Humans With and Without a Complete Truncal Vagotomy",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Does the Vagus Nerve Mediate the Effects of Xenin-25"
      ],
      "interventions": [
        {
          "name": "Graded Glucose Infusion with Placebo",
          "type": "DRUG"
        },
        {
          "name": "Graded Glucose Infusion with GIP Alone",
          "type": "DRUG"
        },
        {
          "name": "Graded Glucose Infusion with xenin-25 alone",
          "type": "DRUG"
        },
        {
          "name": "Graded Glucose Infusion with GIP plus xenin-25",
          "type": "DRUG"
        },
        {
          "name": "Meal Tolerance Test with Placebo",
          "type": "DRUG"
        },
        {
          "name": "Meal Tolerance Test with xenin-25",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Washington University School of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 0,
      "start_date": "2013-01",
      "completion_date": "2018-07",
      "has_results": false,
      "last_update_posted_date": "2018-04-26",
      "last_synced_at": "2026-09-28T11:16:18.159Z",
      "location_count": 1,
      "location_summary": "St Louis, Missouri",
      "locations": [
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01951716"
    },
    {
      "nct_id": "NCT07740291",
      "title": "Tirzepatide Impact Assessment Study",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Obesity & Overweight",
        "Cardiometabolic Health Indicators",
        "Addiction",
        "Eating Disorders",
        "Mental Health"
      ],
      "interventions": [
        {
          "name": "GLP-1 Receptor Agonist Therapy",
          "type": "DRUG"
        },
        {
          "name": "Structured Lifestyle Intervention",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BEHAVIORAL"
      ],
      "sponsor": "Texas Tech University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 27,
      "start_date": "2025-01-02",
      "completion_date": "2026-12-07",
      "has_results": false,
      "last_update_posted_date": "2026-07-31",
      "last_synced_at": "2026-09-28T11:16:18.159Z",
      "location_count": 1,
      "location_summary": "Lubbock, Texas",
      "locations": [
        {
          "city": "Lubbock",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07740291"
    }
  ]
}